Скачать или смотреть Efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with CLL

Efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with CLL

Speaker: Florian SimonInstitution: University Hospital CologneEvent: ASH 2024Format: InterviewSubject: LeukemiaSubject: Chronic lymphocytic leukemiaField: TreatmentField: Trial updatesMedicines: AcalabrutinibMedicines: BTK inhibitorsTrial: CLL-FrailNCT04883749Older patientsFrailty

Скачать Efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with CLL бесплатно в качестве 4к (2к / 1080p)

У нас вы можете скачать бесплатно Efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with CLL или посмотреть видео с ютуба в максимальном доступном качестве.

Для скачивания выберите вариант из формы ниже:

Информация по загрузке:

Cкачать музыку Efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with CLL бесплатно в формате MP3:

Если иконки загрузки не отобразились, ПОЖАЛУЙСТА, НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если у вас возникли трудности с загрузкой, пожалуйста, свяжитесь с нами по контактам, указанным в нижней части страницы.
Спасибо за использование сервиса video2dn.com

Описание к видео Efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with CLL

Florian Simon, MD, University Hospital Cologne, Cologne, Germany, comments on the efficacy and safety of acalabrutinib treatment in very old (≥80y) and/or frail patients with chronic lymphocytic leukemia (CLL). Dr Simon highlights that the CLL-Frail trial (NCT04883749) found that 93% of patients responded to treatment, not only tolerating treatment but also experiencing an improvement in their perceived frailty. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке